A Randomised, db, Placebo-controlled Study of BI 1356 for 18 Weeks Followed by a 34 Week Double-blind Extension Period (Placebo Patients Switched to Glimepiride) in Type 2 Diabetic Patients for Whom Treatment With Metformin is Inappropriate
Launched by BOEHRINGER INGELHEIM · Aug 21, 2008
Trial Information
Current as of June 13, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- • Inclusion criteria Patients between 18 and 80 years old with type 2 diabetes and insufficient glycemic control (HbA1c 7% to 10%) for whom metformin therapy is inappropriate (intolerability or contraindication)
- • Exclusion criteria Myocardial infarction, stroke or Transient ischaemic attack in last 6 months Treatment with rosiglitazone or pioglitazone, GLP-1 analogues, insulin or anti-obesity drugs in past 3 months Impaired hepatic function Severe renal impairment current treatment with systemic steroids change in dosage of thyroid hormones hereditary galactose intolerance
About Boehringer Ingelheim
Boehringer Ingelheim is a global, research-driven pharmaceutical company dedicated to improving health and quality of life through innovative therapies. Established in 1885 and headquartered in Ingelheim, Germany, the company focuses on the development of prescription medicines in key therapeutic areas, including respiratory diseases, cardiovascular health, oncology, and immunology. Boehringer Ingelheim is committed to advancing medical science through rigorous clinical trials and collaborative research, striving to bring novel treatments to patients while upholding the highest standards of safety and efficacy. With a strong emphasis on sustainability and corporate responsibility, the company aims to make a meaningful impact on global health challenges.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Birmingham, Alabama, United States
Peoria, Arizona, United States
Greenbrae, California, United States
Harbor City, California, United States
Huntington Park, California, United States
Los Angeles, California, United States
Miami, Florida, United States
Statesville, North Carolina, United States
Eugene, Oregon, United States
Greer, South Carolina, United States
Kingsport, Tennessee, United States
Dallas, Texas, United States
Dallas, Texas, United States
San Antonio, Texas, United States
San Antonio, Texas, United States
Edmonton, Alberta, Canada
Edmonton, Alberta, Canada
Sarnia, Ontario, Canada
Montague, Prince Edward Island, Canada
Saskatoon, Saskatchewan, Canada
Aguascalientes, , Mexico
Guadalajara, , Mexico
León, , Mexico
Mexico, , Mexico
Mexico, , Mexico
Monterrey, , Mexico
Monterrey, , Mexico
México, , Mexico
México, , Mexico
Cebu, , Philippines
Cebu, , Philippines
Manila, , Philippines
Manila, , Philippines
Marikina, , Philippines
Marikina, , Philippines
Pasay, , Philippines
Pasig, , Philippines
Pasig, , Philippines
Brasov, , Romania
Bucharest, , Romania
Bucharest, , Romania
Galati, , Romania
Sibiu, , Romania
Moscow, , Russian Federation
Moscow, , Russian Federation
St. Petersburg, , Russian Federation
St. Petersburg, , Russian Federation
St. Petersburg, , Russian Federation
Kharkiv, , Ukraine
Kiev, , Ukraine
Kiev, , Ukraine
Lvov, , Ukraine
Vinnitsa, , Ukraine
Patients applied
Trial Officials
Boehringer Ingelheim
Study Chair
Boehringer Ingelheim
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials